Shareholders approve Cytocom-Cleveland BioPharma merger

FORT COLLINS — A proposed merger between Fort Collins-headquartered pharmaceutical company Cytocom Inc. and Cleveland BioLabs Inc. (Nasdaq: CBLI) was approved this week by CBI shareholders and is expected to close in the coming days. 

Upon closure, the combined company — called Cytocom Inc. — will be traded on the Nasdaq exchange under the CYTO ticker symbol.

The deal, approved by a 99.5% majority of voting shareholders, will “enhance our visibility and exposure to public markets,” and “revolutionize the field of immunotherapy,” Cytocom CEO Michael Handley said during a shareholder conference call.

Handley will lead the combined company, along with Cytocom executives and…